#YsiosReport I Ysios Capital’s 2025 / H1 2026 Review is out: strategic transactions, portfolio milestones and growth across the firm. 👉Explore the review ysioscapital.com/wp-content/u... #Biotech #LifeSciences #VC

Show Post

#YsiosNews I #Ipsen to acquire our #portfolio company #MemoTherapeutics 🎯 #Potravitug is a first-in-class monoclonal antibody targeting BK polyomavirus infection in #kidney transplant recipients, a serious complication with no approved treatment. 👉 ysioscapital.com/2026/07/01/i... #vc

Show Post

#YsiosNews I Ysios joins OnaTherapeutics $86.6M Series B to advance first-in-class #ADCs for treatment-resistant cancers. ✅ONA-255 #BreastCancer, toward clinical proof of concept ✅ONA-389 #ColorectalCancer ysioscapital.com/2026/06/04/o... #YsiosPortfolio #vc #biotech #barcelona

Show Post

#PortfolioNews I Inbiomotion continues to expand its #international presence, with distribution partnerships spanning #Spain, #Portugal, #Italy, the #UK & Ireland, Sub-Saharan #Africa and now #SouthKorea. 👉https://buff.ly/OQsIayS #vc #breastcancer #oncology #ysiosportfolio

Show Post

#YsiosTeam I Ysios strengthens team to lead new early-stage vertical. 🚀 🎯Joan Perelló appointed Managing Partner and Arturo Urrios joins as Partner. Full details👉 buff.ly/NX14L8c #Talent #vc #YsiosTeam #Spain #Biotech

Show Post